CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 70 • NUMBER 7 JULY 2003
623
8. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight.
Psychiatr Ann 1999; 29:580–594.
9. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug
treatment: mechanisms and management. Drug Saf 1996; 14:329–342.
10. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a com-
parison study of four medications. Psychiatry Res 1988; 26:265–271.
11. Frank E, Kupfer DJ, Bulik CM, Levenson JA. Imipramine and weight
gain during the treatment of recurrent depression. J Affect Disord
1990; 20:165–172.
12. Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D. Weight
outcomes among antidepressant users in nursing facilities. J Am
Geriatr Soc 2001; 49:49–55.
13. Benazzi F. Weight gain in depression remitted with antidepressants:
pharmacological or recovery effect? Psychother Psychosom 1998;
67:271–274.
14. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with
citalopram. Int Clin Psychopharmacol 1996; 11:273–278.
15. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight
during a 1-year trial of fluoxetine. Am J Psychiatry 1999;
156:1170–1176.
16. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A
placebo-controlled comparison of the antidepressant efficacy and
effects of sexual functioning of sustained release bupropion and ser-
traline. Clin Ther 1999; 21:643–658.
17. Mackle M, Kocsis J. Effects on body weight of the SSRI citalopram.
Presented at the 37th annual meeting of the American College of
Neuropsychopharmacology; Dec 14-18, 1998: Las Croabas, Puerto Rico.
18. Sussman N, Ginsberg D. Rethinking side effects of the selective sero-
tonin reuptake inhibitors: sexual dysfunction and weight gain.
Psychiatr Ann 1998; 28:89–97.
19. American Psychiatric Association. Practice guideline for the treatment
of patients with major depressive disorder (revision). Am J Psychiatry
2000; 157(suppl 4):1–45.
20. Wade A, Overo KF, Lemming O, et al. Weight monitoring during two
long term trials of citalopram. Presented at the 12th Congress of the
European College of Neuropsychopharmacology; Sept 21–25, 1999;
London, England.
21. Hochstrasser B, Isaksen PM. Prophylactic effect of citalopram in unipo-
lar, recurrent depression: placebo-controlled study of maintenance
therapy. Br J Psychiatry 2001; 178:304–310.
22. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine vs sertra-
line and paroxetine in major depressive disorder: changes in weight
with long-term treatment. J Clin Psychiatry 2000; 61:863–867.
23. Agren H, Aberg-Wistedt A, Akerblad AC, et al. Sertraline vs paroxe-
tine in major depression: a multicenter double blind 24 week compari-
son. Presented at the 152nd annual meeting of the APA; May 1999,
Toronto, Ontario, Canada.
24. Fieger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitu-
tion study of nefazodone in the prevention of relapse during continu-
ation treatment of outpatients with major depression. Int Clin
Psychopharmacol 1999; 14:19–28.
25. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body
weight: a pooled analysis of SSRI and imipramine controlled trials. J
Clin Psychiatry 2001; 62:256–260.
26. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ,
Billow AA. Comparison of bupropion and trazodone for the treat-
ment of major depression. J Clin Psychopharmacol 1994; 14:170–179.
27. Feighner J, Hendrickson G, Miller L, Stern W. Double-blind comparison
of doxepin versus bupropion in outpatients with major depressive dis-
order. J Clin Psychopharmacol 1986; 6:27–32.
28. Chouinard G. Bupropion and amitriptyline in the treatment of
depressed patients. J Clin Psychiatry 1983; 44:121–129.
29. Weihs K, Houser T, Batey S, et al. Long-term treatment of depression
with sustained release bupropion. Presented at the 152nd annual meet-
ing of the American Psychiatric Association; May 2000; Chicago, Il.
30. Goodnick PJ, Kremer C. Weight gain during mirtazapine therapy. Prim
Psychiatry 1998; 3:103–108.
31. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs amitripty-
line vs placebo in the treatment of major depressive disorder.
Psychopharmacol Bull 1990; 26:191–196.
32. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitripty-
line in the long-term treatment of depression: a double blind placebo-
controlled study. Int Clin Psychopharmacol 1998; 3:103–108.
33. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine vs ven-
lafaxine in hospitalized severely depressed patients with melancholic
features. Mirtazapine-Venlafaxine Study Group. J Clin
Psychopharmacol 2001; 21:425–431.
34. Stahl SM. Psychopharmacology of antidepressants. London, UK:
Dunitz 1998.
35. Silverstone PH, Ravindran A. Once daily venlafaxine extended release
compared with fluoxetine in outpatients with depression and anxiety.
Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999; 60:22–28.
36. Zajecka JM. Clinical issues in long term treatment with antidepres-
sants. J Clin Psychiatry 2000; 61(suppl 2):20–25.
37. Masand PS. Weight gain associated with psychotropic drugs. Review.
Expert Opinion on Pharmacotherapy 2000; 1:377–389.
ADDRESS: Kathleen Franco, MD, Section of Consultation-Liaison Psychiatry,
Department of Psychiatry and Psychology, P57, The Cleveland Clinic
Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.
on September 10, 2024. For personal use only. All other uses require permission.www.ccjm.orgDownloaded from